Neurological Biomarkers Market Size, Share & Trends Report

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-3-68038-823-7
Number of Pages: 120
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry:Healthcare

Market Segmentation

Neurological Biomarkers Type Outlook (USD Million; 2018 - 2030)
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
Neurological Biomarkers Application Outlook (USD Million; 2018 - 2030)
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
Neurological Biomarkers End-Use Outlook (USD Million; 2018 - 2030)
- Hospital & Hospital Laboratories
- Independent clinical diagnostic centers
- Research Organizations and Others
Neurological Biomarkers Regional Outlook (USD Million; 2018 - 2030)
- North America
  - North America Neurological Biomarkers Market, Type Outlook
    - Genomic
    - Proteomic
    - Metabolomic
    - Imaging
    - Others
  - North America Neurological Biomarkers Application Outlook
    - Alzheimer's Disease
    - Parkinson's Disease
    - Multiple Sclerosis
    - Autism Spectrum Disorder
    - Others
  - North America Neurological Biomarkers End-Use Outlook
    - Hospital & Hospital Laboratories
    - Independent clinical diagnostic centers
    - Research Organizations and Others
  - U.S.
    - U.S. Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - U.S. Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - U.S. Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Canada
    - Canada Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Canada Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Canada Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
- Europe
  - Europe Neurological Biomarkers Type Outlook
    - Genomic
    - Proteomic
    - Metabolomic
    - Imaging
    - Others
  - Europe Neurological Biomarkers Application Outlook
    - Alzheimer's Disease
    - Parkinson's Disease
    - Multiple Sclerosis
    - Autism Spectrum Disorder
    - Others
  - Europe Neurological Biomarkers End-Use Outlook
    - Hospital & Hospital Laboratories
    - Independent clinical diagnostic centers
    - Research Organizations and Others
  - UK
    - UK Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - UK Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - UK Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Germany
    - Germany Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Germany Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Germany Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - France
    - France Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - France Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - France Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Spain
    - Spain Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Spain Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Spain Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Italy
    - Italy Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Italy Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Italy Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Denmark
    - Denmark Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Denmark Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Denmark Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Sweden
    - Sweden Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Sweden Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Sweden Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Norway
    - Norway Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Norway Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Norway Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
- Asia Pacific
  - Asia Pacific Neurological Biomarkers Type Outlook
    - Genomic
    - Proteomic
    - Metabolomic
    - Imaging
    - Others
  - Asia Pacific Neurological Biomarkers Application Outlook
    - Alzheimer's Disease
    - Parkinson's Disease
    - Multiple Sclerosis
    - Autism Spectrum Disorder
    - Others
  - Asia Pacific Neurological Biomarkers End-Use Outlook
    - Hospital & Hospital Laboratories
    - Independent clinical diagnostic centers
    - Research Organizations and Others
  - Japan
    - Japan Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Japan Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Japan Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - China
    - China Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - China Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - China Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - India
    - India Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - India Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - India Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - South Korea
    - South Neurological Biomarkers Korea Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - South Korea Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - South Korea Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Australia
    - Australia Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Australia Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Australia Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Thailand
    - Thailand Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Thailand Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Thailand Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
- Latin America
  - Latin America Neurological Biomarkers Type Outlook
    - Genomic
    - Proteomic
    - Metabolomic
    - Imaging
    - Others
  - Latin America Neurological Biomarkers Application Outlook
    - Alzheimer's Disease
    - Parkinson's Disease
    - Multiple Sclerosis
    - Autism Spectrum Disorder
    - Others
  - Latin America Neurological Biomarkers End-Use Outlook
    - Hospital & Hospital Laboratories
    - Independent clinical diagnostic centers
    - Research Organizations and Others
  - Brazil
    - Brazil Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Brazil Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Brazil Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Mexico
    - Mexico Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Mexico Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Mexico Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Argentina
    - Argentina Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Argentina Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Argentina Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
- Middle East & Africa
  - Middle East & Africa Neurological Biomarkers Type Outlook
    - Genomic
    - Proteomic
    - Metabolomic
    - Imaging
    - Others
  - Middle East & Africa Neurological Biomarkers Application Outlook
    - Alzheimer's Disease
    - Parkinson's Disease
    - Multiple Sclerosis
    - Autism Spectrum Disorder
    - Others
  - Middle East & Africa Neurological Biomarkers End-Use Outlook
    - Hospital & Hospital Laboratories
    - Independent clinical diagnostic centers
    - Research Organizations and Others
  - South Africa
    - 南非的神经生物标记类型前景
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - South Africa Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - South Africa Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Saudi Arabia
    - Saudi Arabia Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Saudi Arabia Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Saudi Arabia Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - UAE
    - UAE Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - UAE Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - UAE Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others
  - Kuwait
    - Kuwait Neurological Biomarkers Type Outlook
      - Genomic
      - Proteomic
      - Metabolomic
      - Imaging
      - Others
    - Kuwait Neurological Biomarkers Application Outlook
      - Alzheimer's Disease
      - Parkinson's Disease
      - Multiple Sclerosis
      - Autism Spectrum Disorder
      - Others
    - Kuwait Neurological Biomarkers End-Use Outlook
      - Hospital & Hospital Laboratories
      - Independent clinical diagnostic centers
      - Research Organizations and Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
乐鱼体育手机网站入口
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.